Alopecia
Chemotherapy-induced alopecia is the next in our series on Foundational #OncoPharm topics.
Aug 27, 2020•19 min
OncoPharm
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episodes
ATAC
Our Landmarks in #OncoPharm Series returns to discuss ATAC: Anastrozole or Tamoxifen Alone or in Combination for adjuvant breast cancer treatment.
Aug 20, 2020•13 min
VIALE-A (venetoclax + azacitidine for elderly/unfit AML)
VIALE-A: Veneoxlax + azacitidine, a new standard of care for elderly or unfit AML patients, is now published. Lots of supportive care and management concerns to discuss: tumor lysis syndrome, prophylactic anti-microbials, G-CSF use (?), and dose modification for hematologic toxicity. Link: https://doi.org/10.1056/nejmoa2012971
Aug 13, 2020•16 min
New Anti-CD-19 And BCMA Options
Lots of new options for B-cell malignancies of all ages! We discuss brexucabtagene autoleucel (CAR-T for mantle cell lymphoma, tafasitamab (anti CD-19 monoclonal antibody), and belantamab mafadotin (anti-BCMA antibody drug conjugate). Finally, for good measure we review the newly approved regimen of atezolizumab with vemurafenib/cobimetinib for BRAF-mutated metastatic melanoma.
Aug 06, 2020•22 min
Gemcitabine
Next up in the Foundations of #OncoPharm series, gemcitabine.
Jul 30, 2020•12 min
Antiemetic & CIPN Guideline Updates
We summarize the changes to ASCO's latest Antiemetic Guidelines update as well as their guidelines for chemotherapy-induced peripheral neuropathy (CIPN). Then, we take a look at the PO decitabine approval and ponder the question, does low albumin decrease tolerability to some TKIs?
Jul 23, 2020•15 min
Conversation With A Breast Cancer Survivor
We're joined by Dr. Karen Fancher, oncology pharmacist, to talk about her breast cancer story from diagnosis to shared-decision making treatment plans with her oncologist to treatment toxicity.
Jul 16, 2020•35 min
Neutropenic Fever 101
While this is a topic best covered with case examples, we do our best to provide the basics in 20 minutes. Experienced clinicians may not be aware of the How Long study briefly discussed in this episode: https://doi.org/10.1016/S2352-3026(17)30211-9
Jul 09, 2020•22 min
Early July FDA Updates
FDA ended June with 5 new approvals. *selinexor for r/r DLBCL *pembrolizumab for cutaneous squamous cell carcinoma *pembrolizumab for MSI-h/dMMR met. colorectal cancer *avelumab maintenance for met. bladder cancer *SC trastuzumab/pertuzumab/hyaluronidase
Jul 02, 2020•13 min
Clinical Trial Endpoints in Oncology
A primer on primary endpoints used in oncology clinical trials. Tailored for those new to in-depth evaluations of oncology literature.
Jun 25, 2020•14 min
Lurbinectedin et al
Topics on this week's Pod include: -Lurbinectedin in SCLC -Nivolumab is esophageal cancer -Pembrolizumab for TMB-high cancers -Gemtuzumab ozogamicin for pediatric AML -Venetoclax + HMA for adult (unfit) AML -Gardasil for prevention of SCCHN -Perhaps the biggest non-oncopharm news of the year?
Jun 18, 2020•18 min
LD Vs Ld
LD Vs Ld by John Bossaer
Jun 11, 2020•12 min
ASCO 2020
Recapping lots of updates from ASCO 2020. Then (20:00) we chat with Shannon Hough, oncology pharmacy specialist, to talk about her ASCO abstract (https://meetinglibrary.asco.org/record/185996/abstract) on pharmacist interventions in managing CINV.
Jun 04, 2020•31 min
More NSCLC Updates (Checkmate-9La & ALTA-1L)
Another week, another two new approved indications in NSCLC. We cover Checkmate-9La (Nivo/Ipi + 2 cycles of chemo) and ALTA-1L (1st Line brigatinib in ALK-rearranged NSCLC). Finally, we cover an interesting case report highlighting the need to determine CNS penetration of kinase inhibitors. (Lots of ASCO talk *next* week!)
May 28, 2020•11 min
New Chemo - Free Immunotherapy Options For NSCLC
There are 2 new Immunotherapy (without chemo) options for untreated metastatic NSCLC. We try to make sense of this evolving landscape. Then, we run through the latest TKI, ripretinib. Finally, we discuss a new approval for Kaposi sarcoma and our obligatory PARP inhibitors update of the week.
May 21, 2020•16 min
Selpercatinib & More!
We now have a RET inhibitor, selpercatinib. This new drug for NSCLC and thyroid cancer is discussed as well as RET in general as a target. Then, we cover olaparib's latest approval for use in conjunction WITH bevacizumab for maintenance in HRD ovarian cancer based on PAOLA-1 (19:30). Finally, we run through IMBrave 150 (atezolizumab + bevacizumab) which may establish a new standard of care in HCC (22:20) and briefly discuss olanzapine for cancer-associated N/V and Ivosidenib for IDH1-mutated cho...
May 14, 2020•30 min
Capmatinib & SC Daratumumab
First, we discuss the FDA approval of daratumumab hyaluronidase for subcutaneous administration and compare its administration to SC administration of rituximab hyaluronidase and trastuzumab hyaluronidase. We end by discussing the 1st FDA-approved drug for MET exon 14 skipping mutations, capmatinib. We also discuss how a receptor tyrosine kinase could skip.
May 08, 2020•16 min
Q 6 Pembro, PARP Inhibitors, MonarcHER, Griffin
Topics of discussion: Q 6 week pembrolizumab dosing schedule FDA approved Updates on possible PARP inhibitor use. Niraparib for ovarian maintenance. Olaparib in prostate cancer (5:28) The monarcHER study of abemaciclib in HER+ MBC (12:20) The GRIFFIN study of Dara+VRD in myeloma (17:00)
Apr 30, 2020•25 min
Sacituzumab Govitecan, Tucatinib, And More!
Five (5!) new #oncopharm products to discuss. First, sacituzumab govitecan. Then, (9:30) tucatinib. Finally, (18:40) mitomycin gel, pemitgatinib, and selumetinib.
Apr 24, 2020•26 min
Journal Club: Unscheduled Hydration in Patients Receiving HEC
Our 1st Journal Club. 1. Read this: https://www.futuremedicine.com/doi/10.2217/fon-2018-0787 2. Ask how, or if, this would change practice. 3. Listen.
Apr 16, 2020•21 min
Bevacizumab's Wild Ride For Metastatic Breast Cancer
First, we run through 4 recent FDA-approved expanded indications for HCC, small cell lung cancer, MDS-related anemia, and BRAF-v600e-mutated colorectal cancer. Then, we review the evidence that warranted bevacizumab's FDA-approval for metastatic breast cancer way back in 2008 (E2100) and its subsequent labeled indication removal by the FDA (Avado & Ribbon-1). Why talk about old news? Perhaps there's a lesson here as we consider using untested drugs... E2100: https://www.nejm.org/doi/full/10....
Apr 09, 2020•13 min
Caravaggio
Reviewing the lasted DOAC study in treating cancer-associated VTE: Caravaggio. We compare it the other major DOAC studies in this patient population. Caravaggio: https://www.nejm.org/doi/full/10.1056/NEJMoa1915103 Also, announcing our first journal club! This will be our 4/16 Pod. It is especially for an oncology APPE students missing out on an oncology experience, but all are welcome to participate. Journal Club link: https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0787
Apr 02, 2020•16 min
Bleomycin
The Foundations of OncoPharm series returns with a unique chemotherapy drug: bleomycin. Also, Covid Thoughs (14:00).
Mar 27, 2020•19 min
Recent Landmarks (CLEOPATRA, Keynote189)
Recent updated survival analyses for CLEOPATRA and Keynote-189 (6:45) require some historical context to truly see their impact. Finally, #AskOncoPharm returns (15:05) with a listener question about infusion rates when restarting daratumumab.
Mar 19, 2020•18 min
*Covid19 And Chemo*
We all should do what we can to "flatten the curve" and that includes our patients on treatment. While there is no such thing as elective chemo, there are some practical ways we can minimize patients needing to come into our facilities.
Mar 16, 2020•9 min
Viz-Aflibercept Pricing: A Case Study
Looking back at a 2012 NYT op-ed (https://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html) that led to a 50% price decrease in a biologic cancer medication.
Mar 12, 2020•8 min
Pre - HOPA News Dunp
A plethora of #oncopharm updates! Isatuximab is approved and neratinib gets another breast cancer indication (2:00) Pembrolizumab with chemo for triple-negative breast cancer (8:50) New EPOC updated survival analysis on FOLFOX+cetuximab in isolated liver metastatic colon cancer (15:00) Precision medicine in pancreatic cancer (19:30) Cladribine + rituximab for hairy cell leukemia (23:30)
Mar 05, 2020•29 min
CYP2D6 & Tamoxifen Updates
Two recent publications add to our knowledge concerning the utility of CYP2D6 genotyping and tamoxifen. TARGET-1: https://www.ncbi.nlm.nih.gov/pubmed/31821071 Tamoxifen D/C rates by 2D6 genotype: https://www.ncbi.nlm.nih.gov/pubmed/31800347
Feb 27, 2020•19 min
CAR - NK
You've heard of CAR-T therapy, and now it's time to learn about CAR-NK cells. Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa1910607
Feb 13, 2020•16 min
NK - 1 Antagonist Drug Interactions
Drug-drug interactions are a key consideration when determining which NK-1 antagonist to use in patients receiving highly emetogenic chemotherapy. We discuss the issues for (fos)aprepitant, netupitant, & rolapitant. A nice aprepitant review (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595939/) and the case for an aprepitant-vincristine interaction (https://doi.org/10.1177/1078155219870840).
Feb 06, 2020•17 min
For the best experience, listen in Metacast app for iOS or Android